

1FW

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as, First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 22, 2007

Signature:

(Joseph A. Williams, Jr.)

Docket No.: 30610/39385A  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Zankel et al.

Application No.: 10/588,425

Confirmation No.: 0

Filed: August 4, 2006

Art Unit: 0

For: MANUFACTURE OF HIGHLY  
PHOSPHORYLATED LYSOSOMAL  
ENZYMES AND USES THEREOF

Examiner: Not Yet Assigned

### INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR

1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30610/39385A.

Dated: March 22, 2007

Respectfully submitted,  
By   
Joseph A. Williams, Jr.  
Registration No.: 38,659  
MARRSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Attorney for Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|                              |   |    |   |                        |                  |
|------------------------------|---|----|---|------------------------|------------------|
| Substitute for form 1449/PTO |   |    |   | Complete if Known      |                  |
|                              |   |    |   | Application Number     | 10/588,425       |
|                              |   |    |   | Filing Date            | August 4, 2006   |
|                              |   |    |   | First Named Inventor   | Zankel et al.    |
|                              |   |    |   | Art Unit               | Not yet assigned |
|                              |   |    |   | Examiner Name          | Not yet assigned |
| Sheet                        | 1 | of | 2 | Attorney Docket Number | 30610/39385A     |

| U.S. PATENT DOCUMENTS |                       |   |                                |  |   |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials*    | Cite No. <sup>1</sup> | Document Number<br>Number-Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|                       |                       | US-4,394,448  | 07-19-1983                     | Szoka, Jr. et al.                                  |   |
|                       |                       | US-5,186,941  | 02-16-1993                     | Callahan et al.                                    |   |
|                       |                       | US-5,962,012  | 10-05-1999                     | Lin et al.   |   |
|                       |                       | US-6,261,595  | 07-17-2001                     | Stanley et al.                                     |   |
|                       |                       | US-6,537,785  | 03-25-2003                     | Canfield   |   |

| FOREIGN PATENT DOCUMENTS |                       |  |                                |  |   |
|--------------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear |
|                          |                       |  |                                |  | T <sup>6</sup>  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS |                       |   |  |  |  |
|---------------------------------|-----------------------|---|--|--|--|
| Examiner Initials               | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                                       |  |  |  |
|                                 |                       | Bräulke et al., "On the Effects of Weak Bases and Monensin on Sorting and Processing of Lysosomal Enzymes in Human Cells," <i>Eur. J. Cell Biol.</i> , 43:316-321 (1987).   |  |  |  |
|                                 |                       | Hoogerbrugge et al., "Allogeneic Bone Marrow Transplantation for Lysosomal Storage Diseases. The European Group for Bone Marrow Transplantation," <i>Lancet</i> , 345:1398-1402 (1995).   |  |  |  |
|                                 |                       | Ioannou et al., "Overexpression of Human Alpha-galactosidase A Results in its Intracellular Aggregation Crystallization in Lysosomes, and Selective Secretion," <i>J. Cell Biology</i> , 119:1137-1150 (1992).  |  |  |  |
|                                 |                       | Kakkis, "Enzyme Replacement Therapy for the Mucopolysaccharide Storage Disorders," <i>Expert Opin. Investig. Drugs</i> , 11:675-685 (2002).   |  |  |  |
|                                 |                       | Marnell et al., "A Chinese Hamster Ovary Cell with a Heat-sensitive, Conditional-lethal Defect in Vacuolar Function," <i>J. Cell Biol.</i> , 99:1907-1916 (1984).   |  |  |  |
|                                 |                       | Munier-Lehmann et al., "Function of the Two Mannose 6-Phosphate Receptors in Lysosomal Enzyme Transport," <i>Biochem. Soc. Trans.</i> , 24:133-136 (1996).  |  |  |  |
|                                 |                       | Nishi et al., "The Vacuolar (H <sup>+</sup> )-ATPases—Nature's Most Versatile Proton Pumps," <i>Nat. Rev. Mol. Cell Biol.</i> , 3:94-103 (2002).  |  |  |  |
|                                 |                       | Park et al., "Biosynthesis of Lysosomal Enzymes in Cells of the END3 Complementation Group Conditionally Defective in Endosomal Acidifications," <i>Somatic Cell and Molecular Genetics</i> , 17:137-150 (1991).  |  |  |  |
|                                 |                       | Van Hove et al., "High Level Production of Recombinant Human Lysosomal Acid Alpha-glucosidase in Chinese Hamster Ovary Cells which Targets to Heart Muscle and Corrects Glycogen Accumulation in Fibroblasts from Patients with Pompe Disease," <i>Proc. Nat. Acad. Sci. (USA)</i> , 93:65-70 (1996). |  |  |  |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|                              |   |    |   |                          |                  |
|------------------------------|---|----|---|--------------------------|------------------|
| Substitute for form 1449/PTO |   |    |   | <i>Complete if Known</i> |                  |
|                              |   |    |   | Application Number       | 10/588,425       |
|                              |   |    |   | Filing Date              | August 4, 2006   |
|                              |   |    |   | First Named Inventor     | Zankel et al.    |
|                              |   |    |   | Art Unit                 | Not yet assigned |
|                              |   |    |   | Examiner Name            | Not yet assigned |
| Sheet                        | 2 | of | 2 | Attorney Docket Number   | 30610/39385A     |

|  |   |
|--|---|
|  | Vellard, "The Enzyme as Drug: Application of Enzymes as Pharmaceuticals," <i>Current Opin. Biotech.</i> , 14:1-7 (2003). <input type="checkbox"/>                     |
|  | Winchester et al., "The Molecular Basis of Lysosomal Storage Diseases and Their Treatment," <i>Biotech. Soc. Trans.</i> , 28:150-154 (2000). <input type="checkbox"/> |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|